Production (Stage)
Akero Therapeutics, Inc.
AKRO
$46.36
-$2.61-5.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -32.58% | -26.89% | -83.33% | -80.12% | -106.51% |
| Total Depreciation and Amortization | -- | 650.00% | -80.00% | -90.91% | -90.91% |
| Total Amortization of Deferred Charges | 58.93% | 45.00% | 41.38% | -65.03% | 12.00% |
| Total Other Non-Cash Items | 29.37% | 64.77% | 54.88% | 54.12% | 32.17% |
| Change in Net Operating Assets | -127.58% | -135.36% | 85.81% | -242.79% | 583.01% |
| Cash from Operations | -92.56% | -37.97% | -41.64% | -156.61% | -42.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -933.52% | 19.44% | 158.13% | -98.67% | 228.87% |
| Cash from Investing | -933.52% | 19.44% | 158.13% | -99.45% | 228.87% |
| Total Debt Issued | -- | -- | -- | -- | -33.33% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.89% | 14,162.66% | 288.46% | -99.90% | 78,235.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -110.22% | 6.45% | -- | -7.92% | 9.57% |
| Cash from Financing | 7.79% | 15,037.65% | 280.52% | -100.04% | 2,321.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -139.60% | 168.40% | 103.27% | -268.40% | 4,703.93% |